Ian Bledsoe, MD

Neurologist

+1 415 353-2311

Dr. Ian Bledsoe is a neurologist specializing in movement disorders like Parkinson’s, tremor, dystonia, and ataxia. He treats patients using medications, botulinum toxin, and deep brain stimulation, with a special focus on dystonia in musicians and others with repetitive motion tasks. His research explores better treatments and the use of neuroimaging to understand dystonia and cognitive issues in Parkinson’s. He trained at Stanford and Rush, holds a master’s in clinical research, and is also an accomplished violinist.

Honors and Awards

The Cheryl Jay Master Clinician Award for Clinical Excellence in Neurology, UCSF, 2021-2022

Jon Stolk Award in Movement Disorders for Young Investigators, American Academy of Neurology, 2020-2021

Neurology Clerkship Teaching Award, Stanford University, 2012-2013

Publications

Abrupt and Severe Onset of Dystonia, Chorea and Hemiplegic Episodes in a Young Boy with a Novel Heterozygous Missense Variant in the GTPase Domain of RHOBTB2.

Movement disorders clinical practice

Hoang PT, Bledsoe IO, San Luciano M

Functional Imaging of Deep Brain Stimulation in Dystonia: A Review

Dystonia

Bledsoe IO, Morrison M.

Parkinsonism of uncertain clinical significance (PUCS): A proposed new diagnostic entity.

Journal of the neurological sciences

Zitser J, Brown EG, Ostrem JL, Tanner CM, Rowe JB, Nguyen V, Rosen H, Geschwind MD, Bledsoe IO

Functional Impairment Preceding Parkinson Disease Diagnosis-What's in a Prodrome?

JAMA neurology

Bledsoe IO, Yu J, Shukla AW

Enhancing Clinical Information Display to Improve Patient Encounters: Human-Centered Design and Evaluation of the Parkinson Disease-BRIDGE Platform.

JMIR human factors

Brown EG, Schleimer E, Bledsoe IO, Rowles W, Miller NA, Sanders SJ, Rankin KP, Ostrem JL, Tanner CM, Bove R

Prefrontal Physiomarkers of Anxiety and Depression in Parkinson's Disease.

Frontiers in neuroscience

de Hemptinne C, Chen W, Racine CA, Seritan AL, Miller AM, Yaroshinsky MS, Wang SS, Gilron R, Little S, Bledsoe I, San Luciano M, Katz M, Chang EF, Dawes HE, Ostrem JL, Starr PA

Commentary: Paraneoplastic Syndrome Associated with Kelch-Like Protein 11 Antibodies Presenting with Progressive Ataxia and Tremor.

Movement disorders clinical practice

Fasano A, Prakash P, Bledsoe IO, Balint B

Paraneoplastic Syndrome Associated with Kelch-Like Protein 11 Antibodies Presenting with Progressive Ataxia and Tremor.

Movement disorders clinical practice

Prakash P, Bledsoe IO

Embedded adaptive deep brain stimulation for cervical dystonia controlled by motor cortex theta oscillations.

Experimental neurology

Johnson V, Wilt R, Gilron R, Anso J, Perrone R, Beudel M, Piña-Fuentes D, Saal J, Ostrem JL, Bledsoe I, Starr P, Little S

Long-term wireless streaming of neural recordings for circuit discovery and adaptive stimulation in individuals with Parkinson's disease.

Nature biotechnology

Gilron R, Little S, Perrone R, Wilt R, de Hemptinne C, Yaroshinsky MS, Racine CA, Wang SS, Ostrem JL, Larson PS, Wang DD, Galifianakis NB, Bledsoe IO, San Luciano M, Dawes HE, Worrell GA, Kremen V, Borton DA, Denison T, Starr PA

Twelve Drummers Drumming… With Dystonia.

Tremor and other hyperkinetic movements (New York, N.Y.)

Bledsoe IO, Reich SG, Frucht SJ, Goldman JG

Thalamic deep brain stimulation for acquired dystonia in children and young adults: a phase 1 clinical trial.

Journal of neurosurgery. Pediatrics

San Luciano M, Robichaux-Viehoever A, Dodenhoff KA, Gittings ML, Viser AC, Racine CA, Bledsoe IO, Watson Pereira C, Wang SS, Starr PA, Ostrem JL

Treatment of Dystonia: Medications, Neurotoxins, Neuromodulation, and Rehabilitation.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics

Bledsoe IO, Viser AC, San Luciano M

Medical education in movement disorders during the COVID-19 pandemic.

Parkinsonism & related disorders

Zuzuárregui JRP, Bledsoe IO, Brown EG, Dietiker CG, Galifianakis NB

FDA Approvals and Consensus Guidelines for Botulinum Toxins in the Treatment of Dystonia.

Toxins

Spiegel LL, Ostrem JL, Bledsoe IO

Phenomenology of Muscle Spasms in Satoyoshi Syndrome and Treatment With Botulinum Toxin Injections.

Movement disorders clinical practice

Bledsoe IO

Phenomenology and Management of Subthalamic Stimulation-Induced Dyskinesia in Patients With Isolated Dystonia.

Movement disorders clinical practice

Bledsoe IO, Dodenhoff KA, San Luciano M, Volz MM, Starr PA, Markun LC, Ostrem JL

Cerebellar Deep Brain Stimulation for Acquired Hemidystonia.

Movement disorders clinical practice

Brown EG, Bledsoe IO, Luthra NS, Miocinovic S, Starr PA, Ostrem JL

Kelch-like Protein 11 Antibodies in Seminoma-Associated Paraneoplastic Encephalitis.

The New England journal of medicine

Mandel-Brehm C, Dubey D, Kryzer TJ, O'Donovan BD, Tran B, Vazquez SE, Sample HA, Zorn KC, Khan LM, Bledsoe IO, McKeon A, Pleasure SJ, Lennon VA, DeRisi JL, Wilson MR, Pittock SJ

White matter abnormalities in the corpus callosum with cognitive impairment in Parkinson disease.

Neurology

Bledsoe IO, Stebbins GT, Merkitch D, Goldman JG

Movement disorder society criteria for clinically established early Parkinson's disease.

Movement disorders : official journal of the Movement Disorder Society

Berg D, Adler CH, Bloem BR, Chan P, Gasser T, Goetz CG, Halliday G, Lang AE, Lewis S, Li Y, Liepelt-Scarfone I, Litvan I, Marek K, Maetzler C, Mi T, Obeso J, Oertel W, Olanow CW, Poewe W, Rios-Romenets S, Schäffer E, Seppi K, Heim B, Slow E, Stern M, Bledsoe IO, Deuschl G, Postuma RB

Publications

Abrupt and Severe Onset of Dystonia, Chorea and Hemiplegic Episodes in a Young Boy with a Novel Heterozygous Missense Variant in the GTPase Domain of RHOBTB2.

Functional Imaging of Deep Brain Stimulation in Dystonia: A Review

Parkinsonism of uncertain clinical significance (PUCS): A proposed new diagnostic entity.

Functional Impairment Preceding Parkinson Disease Diagnosis-What's in a Prodrome?

Enhancing Clinical Information Display to Improve Patient Encounters: Human-Centered Design and Evaluation of the Parkinson Disease-BRIDGE Platform.

Prefrontal Physiomarkers of Anxiety and Depression in Parkinson's Disease.

Commentary: Paraneoplastic Syndrome Associated with Kelch-Like Protein 11 Antibodies Presenting with Progressive Ataxia and Tremor.

Paraneoplastic Syndrome Associated with Kelch-Like Protein 11 Antibodies Presenting with Progressive Ataxia and Tremor.

Embedded adaptive deep brain stimulation for cervical dystonia controlled by motor cortex theta oscillations.

Long-term wireless streaming of neural recordings for circuit discovery and adaptive stimulation in individuals with Parkinson's disease.

Twelve Drummers Drumming… With Dystonia.

Thalamic deep brain stimulation for acquired dystonia in children and young adults: a phase 1 clinical trial.

Treatment of Dystonia: Medications, Neurotoxins, Neuromodulation, and Rehabilitation.

Medical education in movement disorders during the COVID-19 pandemic.

FDA Approvals and Consensus Guidelines for Botulinum Toxins in the Treatment of Dystonia.

Phenomenology of Muscle Spasms in Satoyoshi Syndrome and Treatment With Botulinum Toxin Injections.

Phenomenology and Management of Subthalamic Stimulation-Induced Dyskinesia in Patients With Isolated Dystonia.

Cerebellar Deep Brain Stimulation for Acquired Hemidystonia.

Kelch-like Protein 11 Antibodies in Seminoma-Associated Paraneoplastic Encephalitis.

White matter abnormalities in the corpus callosum with cognitive impairment in Parkinson disease.

Movement disorder society criteria for clinically established early Parkinson's disease.

Validation of the MDS clinical diagnostic criteria for Parkinson's disease.

Corpus callosal atrophy and associations with cognitive impairment in Parkinson disease.

Botulinum Toxin Treatment of Cervical Dystonia.

Oculomotor assessments of executive function in preterm children.